WaveMan
WaveMan · Company
CBIO · Crescent Biopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CBIO Crescent Biopharma (CBIO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001253689
Quote by TradingView
Form 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter

What the filings say about CBIO

Insiders, 180 days
+$10.9M net bought
1 buyer · 7 sellers · 56% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$279.1K
4 notices

Crescent Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CRESCENT BIOPHARMA, INC. insiders bought a net $10.9M of stock across 27 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Brumm Joshua T
Chief Executive Officer
SELL
2026-09-18 SEC
7,837
$131.0K
-18.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 2.9% of the 271,765 shares held after it.
  • 6 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Brumm Joshua T sold about $131.0K of CBIO under a 10b5-1 plan on Sep 18, 2026; 6 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
McNeill Jonathan
President and COO
SELL
2026-09-18 SEC
3,839
$64.1K
-18.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2026.
  • The trade is 2.9% of the 134,588 shares held after it.
  • 6 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and COO McNeill Jonathan sold about $64.1K of CBIO under a 10b5-1 plan on Sep 18, 2026; 6 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
Scalzo Richard William
Chief Financial Officer
SELL
2026-09-18 SECtraded 2026-09-16
568
$10.2K
-18.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 22, 2026.
  • The trade is 2.9% of the 19,730 shares held after it.
  • 6 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Scalzo Richard William sold about $10.2K of CBIO under a 10b5-1 plan on Sep 16, 2026; 6 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
Bispham Barbara Harlin
See Remarks
SELL
2026-09-18 SECtraded 2026-09-16
620
$11.1K
-18.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 22, 2026.
  • The trade is 3.3% of the 18,710 shares held after it.
  • 6 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Bispham Barbara Harlin sold about $11.1K of CBIO under a 10b5-1 plan on Sep 16, 2026; 6 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
Brumm Joshua T
Chief Executive Officer
SELL
2026-09-18 SECtraded 2026-09-16
1,610
$28.8K
-18.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 22, 2026.
  • The trade is 0.6% of the 279,602 shares held after it.
  • 6 other insiders sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Brumm Joshua T sold about $28.8K of CBIO under a 10b5-1 plan on Sep 16, 2026; 6 other insiders sold within 30 days and 49 funds added in the latest 13F quarter.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 22 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$10.9M over 180 days
-$285.5K over 90 days · +$12.4M of it by a 10%+ holder
more than 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
+108340.0% year over year
the highest in Pharma & Biotech
Margin
-1419.6% net margin
below 89% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.4% of the float short (float per yahoo 2026-10-27) · 12.7 days to cover · settled 2026-10-15
more than 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CBIO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.8%12M
-30%+17%+64%+111%2025-102025-122026-022026-042026-062026-082026-10 2025-12-04 · Harwin Peter Evan bought $18.2M2026-07-16 · Fairmount Funds Management LLC bought $12.4M2026-06-22 · Brumm Joshua T sold $761.1K2026-06-22 · McNeill Jonathan sold $369.7K2026-09-18 · Brumm Joshua T sold $131.0K2026-09-18 · McNeill Jonathan sold $64.1K2026-09-16 · Brumm Joshua T sold $28.8K2026-06-22 · Pinkas Jan sold $23.2K2026-06-22 · Im Ellie Eunkyung sold $21.9K2026-06-22 · Bispham Barbara Harlin sold $21.9K2026-06-22 · Scalzo Richard William sold $20.0K2026-09-16 · McNeill Jonathan sold $13.1K2026-09-16 · Pinkas Jan sold $11.8K2026-09-16 · Im Ellie Eunkyung sold $11.2K2026-09-16 · Bispham Barbara Harlin sold $11.1K2026-09-16 · Scalzo Richard William sold $10.2K2026-06-22 · Lynch Ryan sold $8.4K2026-09-16 · Lynch Ryan sold $4.3K2026-09-17 · Joshua T Brumm filed to sell $154.8K2026-09-17 · Jonathan McNeill filed to sell $75.8K2026-09-16 · Joshua T Brumm filed to sell $33.3K2026-09-16 · Jonathan McNeill filed to sell $15.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CBIO: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
4,133,514 sh
$74.4M
BVF INC/IL
2,748,763 sh
$49.5M
Fairmount Funds Management LLC
2,747,866 sh
$49.5M
Venrock Adviser, LLC
2,133,576 sh
$38.4M
Logos Global Management LP
1,900,000 sh
$34.2M

Congress trades in CBIO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CBIO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Joshua T Brumm
Filed 2026-09-17
$154.8K
Jonathan McNeill
Filed 2026-09-17
$75.8K
Joshua T Brumm
Filed 2026-09-16
$33.3K
Jonathan McNeill
Filed 2026-09-16
$15.1K

CBIO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Health Sciences Trust
$107.3K position · as of 2026-06-30
0.0%
Small Cap Index Trust
$80.7K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity ETF
$322.4K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$184.6K position · as of 2026-06-30
0.0%
Nuveen Small Cap Blend Index Fund
$414.7K position · as of 2026-07-31
0.0%
Global X Russell 2000 ETF
$148.7K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · (1)
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.1M
$17.6M
$5.1M
-96%
n/a
2024
$2.9M
$16.2K
$1.4M
-92%
n/a
2023
$2.4M
$1.7M
$1.2M
-22%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $10.9M bought by insiders over 180 days, 49 funds added last quarter, $279.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CBIO financials

Revenue growth
+108340.0%
XBRL, annual
Net margin
-1419.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$73.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-14.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$10.8Mn/a$10.0K$75.0K
Operating income-$152.6M-$40.0M-$39.3M-$47.4M
Net income$153.9K$37.9K$36.9K-$46.7M
EPS (diluted)n/a-0.59-0.58-0.89
Operating cash flow-$71.5M-$31.1M-$34.9M-$46.5M
Cash$213.2M$34.8M$41.8M$47.9M
SEC XBRL, fiscal years, as known on 2026-10-28

CBIO Stock Sonar score 4/7 axes

Find similar shapesCompare

CBIO ranks highest on growth (99th percentile) and insider conviction (76th), and lowest on risk and compliance (11th), among Pharma & Biotech peers.

Growth
100
Inputs
  • Revenue growth, YoY+108340% · 100 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$11.1M · 96 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
46
Inputs
  • Funds adding, latest quarter49 · 46 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
11
Inputs
  • Short interest, % of float+16.4% · 21 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+91.9% · 0 pct, sector of 511
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of operating income; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CBIO filings, in plain words

Are Crescent Biopharma insiders buying or selling CBIO?

In the 180 days to 2026-10-28, Crescent Biopharma insiders were net buyers, a net $10.9M: $12.4M of purchases and $1.5M of sales reported on Form 4, by 1 buyer and 7 sellers.

Are there planned insider sales of CBIO?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $279.1K of stock; the latest, by Joshua T Brumm, was filed 2026-09-17.

Read the full summary

In the 180 days to 2026-10-28, Crescent Biopharma insiders were net buyers of CBIO, a net $10.9M across purchases and sales reported on Form 4 by 1 buyer and 7 sellers. Most of that figure, $12.4M, came from a holder of 10% or more rather than an officer or director. 56% of the 16 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $279.1K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies